Skip to main content

ASH Highlights

Meeting Highlights
ASH Highlights
Minimal Residual Disease After Ixazomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma
Read More
Meeting Highlights
ASH Highlights
Isatuximab + Pomalidomide and Dexamethasone in Frail Patients with RRMM: ICARIA-MM Subgroup Analysis
Read More
Meeting Highlights
ASH Highlights
FORTE Trial: Analysis of Survival in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma
Read More
Meeting Highlights
ASH Highlights
CARTITUDE-1: Ciltacabtagene Autoleucel, a BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy, in RRMM
Read More
Meeting Highlights
ASH Highlights
Idecabtagene Vicleucel, a BCMA-Directed CAR T-Cell Therapy, in Patients with RRMM: CRB-401 Study Updates
Read More
Meeting Highlights
ASH Highlights
Lisocabtagene Maraleucel, a CD19-Directed CAR T-Cell Product, in High-Risk Patients with R/R CLL/SLL, Including Those Previously Treated with Ibrutinib
Read More
Meeting Highlights
ASH Highlights
Three-Year Update of the Phase 2 ABT-199 (Venetoclax) and Ibrutinib in Mantle-Cell Lymphoma (AIM) Study
Read More
Meeting Highlights
ASH Highlights
Bendamustine-Rituximab versus Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma
Read More
Meeting Highlights
ASH Highlights
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory CLL: 42-Month Follow-Up of a Phase 2 Study
Read More
Meeting Highlights
ASH Highlights
ELEVATE TN: Results of a Phase 3 Study of Acalabrutinib in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
Read More
Page 4 of 7
Results 31 - 40 of 70